|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
|
|---|---|---|
| Cash Flows From Operating Activities | ||
| Net income | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based compensation expense | ||
| Deferred income taxes | ||
| Amortization of investments | ||
| Depreciation and amortization | ||
| Impairment of goodwill and intangibles | ||
| Loss on disposal of property and equipment | ||
| Changes in fair value of contingent consideration | ||
| Imputed interest for contingent consideration and in-process R&D | ||
| Other compensation expense | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Inventories | ||
| Prepaid income taxes | ||
| Prepaid expenses and other current assets | ||
| Accounts payable | ||
| Accrued compensation | ||
| Accrued royalties | ||
| Sales-related reserves | ||
| Income taxes payable | ||
| Other accrued liabilities | ||
| Other non-current liabilities | ||
| Net cash provided by operating activities | ||
| Cash Flows From Investing Activities | ||
| Purchase of short-term investments | ||
| Proceeds from the sale and maturities of short-term investments | ||
| Purchase of property, equipment and leasehold improvements | ||
| Restricted cash associated with the acquisition of Synacthen | ||
| Acquisition of BioVectra, net of cash acquired | ||
| Acquisition of Synacthen | ||
| Proceeds from sale of Doral | ||
| Changes in deposits and other assets | ||
| Net cash (used in) / provided by investing activities | ||
| Cash Flows From Financing Activities | ||
| Repayment of funded long-term debt | ||
| Repayment of other long-term debt | ||
| Income tax benefit realized from share-based compensation plans | ||
| Issuance of common stock, net | ||
| Dividends paid | ||
| Repurchase of common stock | ||
| Net cash (used in) / provided by financing activities | ||
| Impact of exchange rate on cash flows | ||
| Increase (decrease) in cash and cash equivalents | ||
| Cash and cash equivalents at beginning of year | ||
| Cash and cash equivalents at end of year | ||
| Supplemental disclosures of Cash Flow Information: | ||
| Cash paid for interest | ||
| Cash paid for income taxes | ||
| Dividend payable | ||
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Capital lease obligation | ||
| Incremental fair value of assets acquired, net | ||
| Fair value of assets acquired | ||
| Foreign currency transaction loss | ||
| Total cash paid for acquisition of BioVectra |
Loading...
